USAMRIID
The U.S. Army Medical Research Institute of Infectious Diseases is the Department of Defense's lead laboratory for medical biological defense research and the only DoD facility with Biosafety Level 4 containment capability. It develops vaccines, drugs, and diagnostics against biological threats and delivers no-cost training to military and civilian healthcare professionals.
- Company typePrivate
- Founded1969
- HeadquartersFrederick, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What USAMRIID does
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), founded in 1969 and headquartered at Fort Detrick, Maryland, is the Department of Defense's lead laboratory for medical biological defense research. It operates the only DoD Biosafety Level 4 maximum containment facility, alongside BSL-3 laboratories, enabling study of the most hazardous viruses and emerging infectious disease threats. The institute's primary customers are the U.S. military Warfighter population, DoD medical commands, and allied public health agencies; secondary audiences include civilian healthcare professionals and partner-nation laboratories in Africa, Asia, and the Americas. USAMRIID's mission is to deliver leading-edge medical capabilities, including vaccines, therapeutics, diagnostics, and training, that deter and defend against current and emerging biological threat agents.
USAMRIID's core technology base centers on BSL-3 and BSL-4 containment infrastructure with positive-pressure encapsulating suits, controlled aerosol exposure systems for animal-model studies, and proprietary antibody discovery workflows that screen survivor blood samples for protective monoclonals. Documented proprietary outputs include the ultra-potent hantavirus antibody (developed with Albert Einstein College of Medicine, effective against multiple strains in animal models), the MAb-9D5 antibody targeting the CCHFV nucleocapsid protein, MBP134 (the first experimental treatment protecting animal models against Sudan Ebola Virus and two other Ebola species), and EVUSHELD (which received FDA emergency use authorization for COVID-19 protection). The institute also maintains a 3D bioprinted vascular liver tissue model, nonhuman primate Ebola virus persistence models, and the Biodefense Reference Material Repository. Research is published in top-tier journals including Science Translational Medicine.
USAMRIID is funded through federal Department of Defense appropriations rather than commercial revenue and operates as a subordinate laboratory of the U.S. Army Medical Research and Development Command (USAMRDC) under the Defense Health Agency. Three in-resident training courses (MCBC, FCBC, HM-CBRNE) and the JKO distance-learning course are delivered at no tuition to military and civilian healthcare professionals via the Army Training Requirements and Resources System. The institute runs a technology transfer and patent licensing program to commercialize research outputs and conducts overseas training in partner nations under the Global Emerging Infection Surveillance program. Marketing channels include the official .mil website, Facebook, Instagram, LinkedIn, the Military Health System Research Symposium, the Maryland STEM Festival, and the One Health Podcast.
USAMRIID firmographics
Firmographics- Name
- USAMRIID
- Legal name
- U.S. Army Medical Research Institute of Infectious Diseases
- Website
- https://usamriid.health.mil
- Company type
- Private
- Founded year
- 1969
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- The U.S. Army Medical Research Institute of Infectious Diseases is the Department of Defense's lead laboratory for medical biological defense research and the only DoD facility with Biosafety Level 4 containment capability. It develops vaccines, drugs, and diagnostics against biological threats and delivers no-cost training to military and civilian healthcare professionals.
- Ownership category
- akta.pro rank
USAMRIID industry classification
Industry- Product category
- Biodefense Research
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Defense R&D, Test, Evaluation & Innovation (BPAIAHAC)
- akta.pro secondary industries
- Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL), Animal Health Emergency Preparedness & Outbreak Response (HLAMAJAD)
Keywords
Where USAMRIID is headquartered
LocationHeadquarters
- HQ city
- Frederick
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
USAMRIID business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Others
Revenue model
- Federal Government Appropriations: As a U.S. Army research institute under the Department of Defense, USAMRIID is funded through federal government appropriations and defense budgets. Research leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical Management of Chemical and Biological Casualties Course (MCBC) - No tuition fees |
| Other | Multi-year contract | Field Management of Chemical & Biological Casualties (FCBC) - No tuition fees |
| Other | Multi-year contract | Hospital Management of CBRNE Incidents Course - No tuition fees |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels11 records
USAMRIID product offering
Product offeringCore offering
USAMRIID is the U.S. Army Medical Research Institute of Infectious Diseases and the Department of Defense's lead laboratory for medical biological defense research. It conducts research in Biosafety Level 3 and the only DoD Biosafety Level 4 maximum-containment laboratories to develop vaccines, therapeutics, diagnostics, and training programs that protect Warfighters and civilians against current and emerging biological threats. It also delivers tuition-free in-resident CBRNE training courses and provides reach-back Subject Matter Expert consultation and Laboratory Response Network capabilities.
Product overview
USAMRIID offers a suite of biodefense products and services centered on research, training, and educational resources for biological threat defense. The core offerings include the USAMRIID Biodefense Tool mobile application for field identification of biological agents, three in-resident training programs (MCBC, FCBC, and HM-CBRNE) providing hands-on education for military and civilian healthcare professionals, and published reference materials including the Blue Book and Quick Bio-Agents Guide. Research conducted at USAMRIID leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians against current and emerging biological threat agents.
Differentiator
Problem solved
Functional benefit
Products and services
- USAMRIID Biodefense Tool Mobile Application
- Medical Management of Chemical and Biological Casualties Course (MCBC)
- Field Management of Chemical & Biological Casualties (FCBC)
- Hospital Management of Chemical, Biological, Radiological, Nuclear & Explosive Incidents (HM-CBRNE)
- Medical Management of Biological Casualties Handbook (Blue Book)
- Quick Bio-Agents Guide (Pocket Reference Guide to Biological Select Agents & Toxins)
- JKO Medical Management of Biological Casualties Course
- Textbook of Military Medicine - Medical Aspects of Biological Warfare
Quantifiable outcome
- First monoclonal antibody to demonstrate cross-protective efficacy against both Old and New World hantaviruses
- +3 more outcomes
Companies that use USAMRIID
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
USAMRIID technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
USAMRIID partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights6 records
USAMRIID competitors and assessment
Company assessmentDirect peers
- Walter Reed Army Institute of Research (WRAIR): Sister U.S. Army medical research institute under USAMRDC; conducts infectious disease and military medicine R&D and shares the same parent command and research-mission posture as USAMRIID.
- MRIGlobal: Independent nonprofit research organization operating BSL-3/BSL-4 facilities and providing infectious-disease and CBRN research services to federal clients, including DoD.
- U.S. Army Medical Research Institute of Chemical Defense (USAMRICD): Co-located DoD medical defense institute focused on chemical casualties; partners with USAMRIID on joint CBRNE training courses (FCBC, HM-CBRNE) at Aberdeen Proving Ground.
- United States Army Medical Materiel Development Activity (USAMMDA): U.S. Army activity that develops and fields FDA-regulated medical products; downstream counterpart to USAMRIID's discovery-stage R&D within the same USAMRDC command structure.
Emerging players
- Battelle Memorial Institute: Nonprofit applied R&D provider with extensive government and defense contracts in life sciences, biodefense, and CBRN — comparable as a federal-contracting research-services peer.
- Lovelace Biomedical & Environmental Research Institute: Private nonprofit with BSL-3 and BSL-4 capabilities, performing infectious-disease and aerosol-exposure animal-model research for government and biodefense clients.
Broad incumbents
- National Institute of Allergy and Infectious Diseases (NIAID): Larger U.S. government funder and performer of infectious-disease R&D; the primary civilian counterpart to USAMRIID for BSL-4 pathogen research, vaccine development, and outbreak response.
- Centers for Disease Control and Prevention (CDC): Federal public health agency with overlapping laboratory and outbreak-response mandates; co-developed the FDA-approved anthrax test with USAMRIID and partners on select-agent diagnostics.
- Biomedical Advanced Research and Development Authority (BARDA): HHS office that funds late-stage development of medical countermeasures; a key downstream partner for USAMRIID-discovered vaccines and therapeutics that move toward FDA approval.
- Defense Advanced Research Projects Agency (DARPA): DoD R&D agency funding high-risk biological and health research; overlapping funder/partner for advanced biodefense technology programs relevant to USAMRIID's mission.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
USAMRIID social profiles
Digital presenceUSAMRIID financial estimates
Financial estimateRevenue estimate
Valuation estimate
USAMRIID leadership team
Management profileNumber of profiles
Profiles1 record
USAMRIID funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
USAMRIID M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about USAMRIID
What does USAMRIID do?
USAMRIID is the U.S. Army Medical Research Institute of Infectious Diseases and the Department of Defense's lead laboratory for medical biological defense research. It conducts research in Biosafety Level 3 and the only DoD Biosafety Level 4 maximum-containment laboratories to develop vaccines, therapeutics, diagnostics, and training programs that protect Warfighters and civilians against current and emerging biological threats. It also delivers tuition-free in-resident CBRNE training courses and provides reach-back Subject Matter Expert consultation and Laboratory Response Network capabilities.
Is USAMRIID a public or private company?
USAMRIID is a private company. It is classified as state government owned and is currently operating.
When was USAMRIID founded?
USAMRIID was founded in 1969. It employs 501 to 1,000 people.
Where is USAMRIID based?
USAMRIID is headquartered in Frederick, United States, in the North America region.
How does USAMRIID make money?
One revenue line is on record: federal Government Appropriations.
Who are USAMRIID's main competitors?
Direct peers on record are Walter Reed Army Institute of Research (WRAIR), MRIGlobal, U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and United States Army Medical Materiel Development Activity (USAMMDA). Emerging players are Battelle Memorial Institute and Lovelace Biomedical & Environmental Research Institute. Broad incumbents are National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA) and Defense Advanced Research Projects Agency (DARPA).
Does USAMRIID have an API?
No public API is recorded for USAMRIID.
What industry is USAMRIID in?
USAMRIID's product category is Biodefense Research. Its primary akta.pro industry code is BPAIAHAC, Defense R&D, Test, Evaluation & Innovation, with a secondary code of HLAJAIAL, Biothreat/Biocontainment & Select Agent Public Health Laboratories. Its NAICS code is 5417 and its SIC code is 8731.